ARTL Artelo Biosciences: חוב לטווח קצר של החברה

The market value dynamics of Artelo Biosciences (ARTL), where the individual debt metric stands at 0.00, align with data on compliance with basic eco-standards in laboratories. Artelo Biosciences develops cannabinoid receptor-based agents to combat cancer cachexia, ensuring stable profits through its patents. Revenue is generated through partnerships with insurance companies and oncology centers that pay for supportive therapy for patients with chronic pain.

This metric aggregates all credit obligations of Artelo Biosciences (ARTL) with a maturity of up to one year, reflecting the current debt load and liquidity risk. By analyzing short-term borrowed capital, an investor assesses the biopharmaceutical firm's ability to fund laboratory research without emergency asset sales, given that the company's environmental costs are minimal and do not create additional financial burdens.